TN2013000392A1 - Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor - Google Patents

Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

Info

Publication number: TN2013000392A1
Authority: TN; Tunisia
Prior art keywords: inhibitor; combination; kinase; pi3k; phosphatidylinositol
Prior art date: 2011-04-25

Application number

TNP2013000392A

Other languages

English (en)

Inventor

Christine Fritsch

Carlos Garcia-Echeverria

Xizhong Huang

Sauveur-Michel Maira

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-25

Filing date

2013-09-27

Publication date

2015-01-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46018130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000392(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-09-27 Application filed by Novartis Ag filed Critical Novartis Ag

2015-01-20 Publication of TN2013000392A1 publication Critical patent/TN2013000392A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Gastroenterology & Hepatology (AREA)
Gynecology & Obstetrics (AREA)

TNP2013000392A 2011-04-25 2013-09-27 Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor TN2013000392A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161478572P	2011-04-25	2011-04-25
PCT/US2012/034647 WO2012148846A1 (fr)	2011-04-25	2012-04-23	Association d'un inhibiteur de phosphatidylinositol-3-kinase (pi3k) et d'un inhibiteur de mtor

Publications (1)

Publication Number	Publication Date
TN2013000392A1 true TN2013000392A1 (en)	2015-01-20

Family

ID=46018130

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2013000392A TN2013000392A1 (en)	2011-04-25	2013-09-27	Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

Country Status (26)

Country	Link
US (3)	US20140066474A1 (fr)
EP (1)	EP2701703A1 (fr)
JP (2)	JP6086902B2 (fr)
KR (1)	KR101925656B1 (fr)
CN (1)	CN103491955B (fr)
AR (1)	AR086481A1 (fr)
AU (2)	AU2012250010A1 (fr)
BR (1)	BR112013027486A2 (fr)
CA (1)	CA2833962A1 (fr)
CL (1)	CL2013003078A1 (fr)
CO (1)	CO6801759A2 (fr)
EA (1)	EA025948B1 (fr)
EC (1)	ECSP13012994A (fr)
GT (1)	GT201300263A (fr)
IL (1)	IL229008A (fr)
MA (1)	MA35038B1 (fr)
MX (1)	MX2013012385A (fr)
NZ (1)	NZ615593A (fr)
PE (1)	PE20140601A1 (fr)
PH (1)	PH12013502077A1 (fr)
SG (1)	SG193919A1 (fr)
TN (1)	TN2013000392A1 (fr)
TW (1)	TWI602567B (fr)
UA (1)	UA110961C2 (fr)
WO (1)	WO2012148846A1 (fr)
ZA (1)	ZA201306973B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2012331125A1 (en) *	2011-11-02	2014-05-22	Novartis Ag	2-carboxamide cycloamino urea derivatives for use in treating VEGF - dependent diseases
CN105246482A (zh) *	2013-03-15	2016-01-13	因特利凯有限责任公司	激酶抑制剂的组合及其用途
US20150140036A1 (en) *	2013-11-13	2015-05-21	Novartis Institutes For Biomedical Research, Inc.	Low, immune enhancing, dose mtor inhibitors and uses thereof
US20170165246A1 (en) *	2014-02-11	2017-06-15	Novartis Ag	Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer
WO2015148626A1 (fr) *	2014-03-26	2015-10-01	Millennium Pharmaceuticals, Inc.	Traitement d'affections fibrotiques
RU2690685C2 (ru) *	2014-10-03	2019-06-05	Новартис Аг	Фармацевтические композиции, содержащие алпелисиб
US20160339030A1 (en) *	2015-05-19	2016-11-24	University Of Maryland, Baltimore	Treatment agents for inhibiting hiv and cancer in hiv infected patients
JP6691337B2 (ja) *	2016-02-29	2020-04-28	学校法人北里研究所	膀胱癌患者の予後を予測するための方法
GB202010627D0 (en) *	2020-07-10	2020-08-26	Qbd (Qs-Ip) Ltd	Blocking method

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT98990A (pt)	1990-09-19	1992-08-31	American Home Prod	Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5120842A (en)	1991-04-01	1992-06-09	American Home Products Corporation	Silyl ethers of rapamycin
US5100883A (en)	1991-04-08	1992-03-31	American Home Products Corporation	Fluorinated esters of rapamycin
US5118678A (en)	1991-04-17	1992-06-02	American Home Products Corporation	Carbamates of rapamycin
US5118677A (en)	1991-05-20	1992-06-02	American Home Products Corporation	Amide esters of rapamycin
US5151413A (en)	1991-11-06	1992-09-29	American Home Products Corporation	Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en)	1991-12-03	1992-01-29	Smithkline Beecham Plc	Novel compound
ZA935111B (en)	1992-07-17	1994-02-04	Smithkline Beecham Corp	Rapamycin derivatives
ZA935112B (en)	1992-07-17	1994-02-08	Smithkline Beecham Corp	Rapamycin derivatives
US5256790A (en)	1992-08-13	1993-10-26	American Home Products Corporation	27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en)	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
US5258389A (en)	1992-11-09	1993-11-02	Merck & Co., Inc.	O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
JP4105761B2 (ja)	1993-11-19	2008-06-25	アボット・ラボラトリーズ	ラパミシン（マクロライド）の半合成類似体免疫調節剤
CZ284650B6 (cs)	1993-12-17	1999-01-13	Novartis Ag	Nové demethoxyderiváty rapamycinu, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
KR100400620B1 (ko)	1995-06-09	2004-02-18	노파르티스 아게	라파마이신유도체
EP0937082A2 (fr)	1996-07-12	1999-08-25	Ariad Pharmaceuticals, Inc.	Elements et procedes pour traiter ou prevenir les mycoses pathog nes
ES2219388T3 (es)	1999-08-24	2004-12-01	Ariad Gene Therapeutics, Inc.	28-epi-rapalogos.
TW200519106A (en) *	2003-05-02	2005-06-16	Novartis Ag	Organic compounds
CN102579467A (zh) *	2005-11-14	2012-07-18	阿里亚德医药股份有限公司	雷帕霉素衍生物在治疗癌症中的用途
UA104147C2 (uk) *	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
RU2538683C2 (ru) *	2008-10-31	2015-01-10	Новартис Аг	КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (Р13К) И ИНГИБИТОРА mTOR

2012
- 2012-04-23 BR BR112013027486A patent/BR112013027486A2/pt not_active Application Discontinuation
- 2012-04-23 JP JP2014508463A patent/JP6086902B2/ja not_active Expired - Fee Related
- 2012-04-23 UA UAA201311138A patent/UA110961C2/uk unknown
- 2012-04-23 PH PH1/2013/502077A patent/PH12013502077A1/en unknown
- 2012-04-23 WO PCT/US2012/034647 patent/WO2012148846A1/fr not_active Ceased
- 2012-04-23 US US14/113,316 patent/US20140066474A1/en not_active Abandoned
- 2012-04-23 KR KR1020137027718A patent/KR101925656B1/ko not_active Expired - Fee Related
- 2012-04-23 MA MA36325A patent/MA35038B1/fr unknown
- 2012-04-23 CN CN201280020528.4A patent/CN103491955B/zh not_active Expired - Fee Related
- 2012-04-23 SG SG2013070461A patent/SG193919A1/en unknown
- 2012-04-23 CA CA2833962A patent/CA2833962A1/fr not_active Abandoned
- 2012-04-23 EA EA201391565A patent/EA025948B1/ru not_active IP Right Cessation
- 2012-04-23 MX MX2013012385A patent/MX2013012385A/es unknown
- 2012-04-23 NZ NZ615593A patent/NZ615593A/en not_active IP Right Cessation
- 2012-04-23 PE PE2013002391A patent/PE20140601A1/es not_active Application Discontinuation
- 2012-04-23 AU AU2012250010A patent/AU2012250010A1/en not_active Abandoned
- 2012-04-23 EP EP12717568.5A patent/EP2701703A1/fr not_active Withdrawn
- 2012-04-23 AR ARP120101389A patent/AR086481A1/es unknown
- 2012-04-24 TW TW101114591A patent/TWI602567B/zh not_active IP Right Cessation
2013
- 2013-09-17 ZA ZA2013/06973A patent/ZA201306973B/en unknown
- 2013-09-27 TN TNP2013000392A patent/TN2013000392A1/fr unknown
- 2013-10-21 IL IL229008A patent/IL229008A/en active IP Right Grant
- 2013-10-24 CL CL2013003078A patent/CL2013003078A1/es unknown
- 2013-10-24 CO CO13252726A patent/CO6801759A2/es not_active Application Discontinuation
- 2013-10-25 EC ECSP13012994 patent/ECSP13012994A/es unknown
- 2013-10-25 GT GT201300263A patent/GT201300263A/es unknown
2016
- 2016-04-14 AU AU2016202372A patent/AU2016202372B2/en not_active Ceased
- 2016-10-27 US US15/335,957 patent/US20170095463A1/en not_active Abandoned
- 2016-11-18 JP JP2016224893A patent/JP2017061527A/ja active Pending
2017
- 2017-09-26 US US15/715,865 patent/US20180085362A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2017061527A (ja)	2017-03-30
AU2016202372B2 (en)	2017-07-20
PE20140601A1 (es)	2014-05-24
EA025948B1 (ru)	2017-02-28
KR101925656B1 (ko)	2018-12-05
US20180085362A1 (en)	2018-03-29
MA35038B1 (fr)	2014-04-03
SG193919A1 (en)	2013-11-29
UA110961C2 (uk)	2016-03-10
US20140066474A1 (en)	2014-03-06
CL2013003078A1 (es)	2014-05-30
NZ615593A (en)	2015-05-29
CO6801759A2 (es)	2013-11-29
TWI602567B (zh)	2017-10-21
EA201391565A1 (ru)	2014-02-28
KR20140012147A (ko)	2014-01-29
WO2012148846A1 (fr)	2012-11-01
US20170095463A1 (en)	2017-04-06
IL229008A0 (en)	2013-12-31
TW201244716A (en)	2012-11-16
CN103491955B (zh)	2015-12-23
CN103491955A (zh)	2014-01-01
GT201300263A (es)	2015-11-24
AR086481A1 (es)	2013-12-18
AU2016202372A1 (en)	2016-05-05
CA2833962A1 (fr)	2012-11-01
ECSP13012994A (es)	2013-12-31
ZA201306973B (en)	2014-06-25
JP6086902B2 (ja)	2017-03-01
MX2013012385A (es)	2013-11-04
AU2012250010A1 (en)	2013-10-10
PH12013502077A1 (en)	2013-12-16
IL229008A (en)	2017-11-30
JP2014513097A (ja)	2014-05-29
EP2701703A1 (fr)	2014-03-05
BR112013027486A2 (pt)	2017-02-14

Publication	Publication Date	Title
TN2013000392A1 (en)	2015-01-20	Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
PH12018501807A1 (en)	2019-03-25	Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
EA201692506A3 (ru)	2017-10-31	Ингибиторы репликации вирусов гриппа
PH12014502757B1 (en)	2015-03-02	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX2011011335A (es)	2011-11-18	Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
NZ724503A (en)	2017-12-22	Macrocyclic inhibitors of flaviviridae viruses
MD20140135A2 (ro)	2015-05-31	Inhibitori macrociclici ai viruşilor din familia Flaviviridae
AU2012284088A8 (en)	2014-05-01	Heterocyclic compounds and uses thereof
MX2013006475A (es)	2013-11-01	Inhibidores macrociclicos de virus flaviviridae.
MX2013012588A (es)	2014-05-20	Inhibidores de cinasa.
MX2009008486A (es)	2009-08-20	Imidazoquinolinas como inhibidores dobles de cinasa de lipido y mtor.
GEP201706624B (en)	2017-02-10	Triazolopyrazine as brd4 inhibitors and usage thereof for cancer treatment
NZ703066A (en)	2016-10-28	Macrocyclic inhibitors of flaviviridae viruses
NZ703064A (en)	2016-12-23	Inhibitors of hepatitis c virus
UA114906C2 (uk)	2017-08-28	Гетероциклільні сполуки як інгібітори мек
EA201000091A1 (ru)	2010-06-30	ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
EA201390198A1 (ru)	2013-11-29	Гетероциклическое соединение
MX2015016421A (es)	2016-03-03	Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
CL2014000849A1 (es)	2014-08-29	Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
NZ706591A (en)	2016-03-31	Oxazolidin-2-one-pyrimidine derivatives
MX2014004559A (es)	2014-08-01	Derivados de 2-carboxamida cicloamino urea en combinacion con inhibidores de hsp90 para el tratamiento de enfermedades proliferativas.
EA032271B9 (ru)	2019-08-30	Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12013500581A1 (en)	2013-05-20	Pharmaceutical combinations
GEP201706614B (en)	2017-02-10	Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
EA201500366A1 (ru)	2015-12-30	Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора